

Tsunetoshi Shimazu - Pediatric Advisory Committee Open Public Hearing -
02-15-05

Urgent attention for Dr.Chesney and members of the committee. Please
deliver to her personally.

Dear Dr. Chesney,

I have known that on Monday, February 15, 2005, the Pediatric
Advisory
Committee will discuss on potential cancer risk among pediatric
patients treated for atopic dermatitis with topical dermatological
immunosuppressants.

I would like to send you a copy of my abstract paper for submission
at
the WAC 2005 Conference (my paper is yet to be accepted) concerning the
case of a Sezary syndrome girl (the same patient as your AERS ISR
NUMBER 4251585-X) together with her pictures and the attached letter to
you and your committee members. As you will see from my paper and
attached letter, I believe that topical Tacrolimus therapy for AD
patients may increase the risk of malignant disease such as CTCL and
lymphoma and other life-threatening diseases.

I would be most grateful if you and your committee would consider my
findings and issue warnings regarding the tremendous dangers related to
topical immunosuppressant such as Tacrolimus and Elidel.

I would also very grateful if you could email me regarding the matter I
have presented to you with any comments or any advise you may have for
me.

Yours faithfully,

Tsunetoshi Shimazu M.D.

Shimazu Clinic

31 Higashitakada-cho, Mibu, Nakagyo-ku,
Kyoto, 604-8845 Japan

Phone: +81 75 311 1902

Fax: +81 75 322 1633

e-mail: shimazu-clinic@giga.ocn.ne.jp